Home > Legislation > 115th Congress > H.R.2851

H.R.2851 - SITSA Act115th Congress (2017-2018) |

Bill

Hide Overview
Sponsor: Rep. Katko, John [R-NY-24] (Introduced 06/08/2017)
Committees: House - Energy and Commerce; Judiciary | Senate - Judiciary
Committee Reports: H. Rept. 115-713
Latest Action: Senate - 06/18/2018 Received in the Senate and Read twice and referred to the Committee on the Judiciary.  (All Actions)
Roll Call Votes: There have been 2 roll call votes

Tracker:

This bill has the status Passed House

Here are the steps for Status of Legislation:

  1. Introduced
  2. Passed House
  3. Passed Senate
  4. To President
  5. Became Law

More on This Bill

  • Constitutional Authority Statement
  • CBO Cost Estimates [1]

Subject — Policy Area:

Summary: H.R.2851 — 115th Congress (2017-2018)All Information (Except Text)

There is one summary for H.R.2851. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (06/08/2017)

Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 or the SITSA Act

This bill amends the Controlled Substances Act to establish a new, sixth schedule of controlled substances—schedule A. A drug or substance in schedule A has a chemical structure that is similar to, and an effect on the body that is similar to or greater than, a controlled substance in schedule I, II, III, IV, or V.

The bill adds 13 synthetic fentanyl-related substances to schedule A. It also authorizes, and establishes procedures for, the Drug Enforcement Administration (DEA) to temporarily and permanently place a drug or substance in schedule A.

The bill establishes criminal penalties for an individual who imports, exports, manufactures, distributes, or possesses with intent to distribute a schedule A substance. However, it explicitly prohibits criminal and civil penalties solely for possession of a schedule A controlled substance.

The bill makes it unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, a schedule A substance that is not clearly labeled.

Finally, it establishes new, separate DEA registration requirements for manufacturers, distributors, and importers and exporters of schedule A substances.